Vitamin D Supplementation in IBS
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03148288 |
Recruitment Status :
Terminated
(low enrollment)
First Posted : May 10, 2017
Last Update Posted : May 6, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Irritable bowel syndrome (IBS) is a very common functional gastrointestinal disorder affecting nearly 20% of the North American population. IBS is characterized by chronic abdominal, associated with a change in bowel frequency and or consistency that lack a known structural or anatomic explanation. Current treatment for IBS is primarily symptom-based. However over a third of patients with IBS fail to respond to currently available therapies.
The prevalence of vitamin D deficiency/insufficiency is estimated in over a billion people world-wide . Vitamin D has potential mechanisms not only in the balance of calcium and bone homeostasis, but also a key modulator of the immune system. Vitamin D receptors (VDRs) are located on all nucleated cells including the GI tract. Thus far, there is already accumulating evidence for a role for vitamin D supplementation in inflammatory bowel disease (IBD). A recent systematic review suggested there may be benefits of vitamin D supplementation in IBD.
Vitamin D insufficiency is widespread in patients with IBS and there is a positive association between vitamin D status and quality of life. To date, there is no US trial examining the effect of vitamin d supplementation on IBS symptoms and quality of life in patients with IBS.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Irritable Bowel Syndrome Vitamin D Deficiency Abdominal Pain | Dietary Supplement: Vitamin D Dietary Supplement: placebo | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 7 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Other |
Official Title: | Vitamin D Supplementation in IBS |
Actual Study Start Date : | September 1, 2017 |
Actual Primary Completion Date : | March 20, 2018 |
Actual Study Completion Date : | March 20, 2018 |
Arm | Intervention/treatment |
---|---|
Experimental: Vitamin D supplementation
4000IU Vitamin D qd
|
Dietary Supplement: Vitamin D
VItamin D |
Placebo Comparator: placebo |
Dietary Supplement: placebo
placebo |
- Irritable Bowel Syndrome - Symptom Severity Scale (IBS-SSS) [ Time Frame: 12 weeks ]VAS on abdominal symptoms

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Provide signed and dated informed consent and understand the nature of the study sufficiently to allow completion of all study assessments.
- Be ambulatory, community dwelling, 18 to 80 years, inclusive
- Meet Rome IV diagnostic criteria for IBS
- Have IBS of at least "moderate" severity, i.e., have a score on the IBS-SSS of > 175 (0-500) at the baseline visit (Visit 1)
- If the patient is on medications which affect the gastrointestinal tract or visceral sensation (e.g., tricyclic antidepressants, fiber, antispasmodics, etc.) they must be on a stable dose for at least 1 month prior to entering the study and for the duration of the study.
Exclusion Criteria:
- Have a history of intractable IBS, defined as continuous, unremitting and severe abdominal pain.
- Be pregnant or lactating.
- Have an established diagnosis of any concomitant bowel disturbance that would interfere with the assessment of efficacy or safety in the study (e.g., Hirschsprung's disease, inflammatory bowel disease, celiac disease).
- Report warning symptoms (i.e., rectal bleeding, weight loss >10%, iron deficiency anemia, etc.) otherwise not explained
- Have undergone previous abdominal surgery (with the exception of uncomplicated appendectomy, cholecystectomy, hysterectomy, or polypectomy > 6 months prior to enrollment).
- Have a history of metabolic or inflammatory disease that may affect bowel motility (e.g., inflammatory bowel disease, celiac, sarcoidosis, connective tissue disease, amyloidosis, or poorly controlled hypo/hyperthyroidism).
- Have a history of significant concomitant psychiatric, neurological, metabolic, hepatic, renal, infectious, hematological, cardiovascular, gastrointestinal, or pulmonary illness. If there is a history of such disease but the condition has been stable for more than one year and is judged by the Investigator not to interfere with the patient's participation in the study, the patient may be included. Staff will document such cases.
- Have a history of drug, excluding nicotine or caffeine, or alcohol abuse within 2 years of entry into the study
- Exhibit abnormalities on physical examination, have abnormal vital signs, or clinical laboratory values, unless these abnormalities are judged to be clinically insignificant by the Investigator. Such cases will be noted.
- Active laxative abuse.
- Unable or unwilling to cooperate with the study protocol or considered by the Investigator to be unsuitable for the study.
- Currently taking Vitamin D supplements
- Diagnosis of osteoporosis
- Currently bisphosphonate medications
- Those who taking medication known to interfere with Vit D

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03148288
United States, Massachusetts | |
Beth Israel Deaconess Medical Center | |
Boston, Massachusetts, United States, 02215 |
Responsible Party: | Beth Israel Deaconess Medical Center |
ClinicalTrials.gov Identifier: | NCT03148288 |
Other Study ID Numbers: |
2017P000133 |
First Posted: | May 10, 2017 Key Record Dates |
Last Update Posted: | May 6, 2020 |
Last Verified: | May 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Irritable Bowel Syndrome Vitamin D Deficiency Abdominal Pain Colonic Diseases, Functional Colonic Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases Avitaminosis Deficiency Diseases |
Malnutrition Nutrition Disorders Pain Neurologic Manifestations Signs and Symptoms, Digestive Vitamin D Vitamins Micronutrients Physiological Effects of Drugs Bone Density Conservation Agents |